Bone morphogenetic proteins in soft-tissue reconstruction.
Different options are reviewed in the field of musculoskeletal tissue reconstruction, from the addition of biological actors (cells, growth factors, biological or artificial scaffolds) to the application of gene therapy or tissue engineering. Growth factors can enable innovative solutions to treat such disease if we can extrapolate to soft tissue the promising results obtained in bone reconstruction with bone morphogenetic proteins. However, as in bone reconstruction, soft-tissue regeneration will depend on the drug delivery carrier, the scaffold for the newly formed tissue, the dose of growth factor and the animal model, which must all be explored before extrapolation to clinical problems.
Obert
L
L
Orthopaedic, Traumatology, Plastic and Hand Surgery Unit, University of Franche Comté, CHU Jean Minjoz, Besancon, France. lobert@chu-besancon.fr
Lepage
D
D
Gindraux
F
F
Garbuio
P
P
D000818:Animals; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage*; D002356:Cartilage / Q000293:injuries / Q000601:surgery; D002465:Cell Movement; D004195:Disease Models, Animal; D004337:Drug Carriers; D048091:Guided Tissue Regeneration / Q000379:methods; D006801:Humans; D007267:Injections; D055959:Intervertebral Disc Degeneration / Q000628:therapy; D008022:Ligaments / Q000293:injuries; D059630:Mesenchymal Stem Cells / Q000187:drug effects / Q000502:physiology; D011817:Rabbits; D051381:Rats; D011994:Recombinant Proteins / Q000008:administration & dosage*; D017695:Soft Tissue Injuries / Q000628:therapy*; D013708:Tendon Injuries / Q000628:therapy; D054457:Tissue Scaffolds; D016212:Transforming Growth Factor beta / Q000008:administration & dosage*
D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D004337:Drug Carriers; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2